


Intensity Therapeutics, Inc. (INTS)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001567264

Intensity Therapeutics, Inc.		
INTS; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescansplit-adjusted close; the letter is fixed at the rescans that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$14.1M	
Warnings	dilution, thin data, distress not computable: degenerate inputs, fortress balance sheet	
Inputs computable	5 of 14	
Graded from	filings received through Mar 27, 2026 196 days before the rescans; latest periodic filing 10-Q received Aug 11, 2026	
Last close	\$3.61 2026-10-05; market equity \$11.8M	
Price used in grade	None	

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRxSM discovery platform. Intratumoral ("IT") treatment, or treatment designed to contain a drug inside a tumor without spreading to the rest of the body, has been an objective of clinicians since discovery of chemotherapeutic agents.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 17.3						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(25.1%)	(6.6%)	17.3	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 63.1						
Twelve-month failure probability		1.77%	0.07%	91.1	248	2026-06-30
Altman Z double-prime		(13.31)	(0.31)	67.3	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		5.92x	2.96x	31.0	839	2025-12-31
Growth and financing, sleeve percentile 92.1						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 0
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		not computable	2.1%			four annual observations are required; found 3
Net share issuance, one year		318.4%	2.5%	92.1	634	2026-03-26

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 318.4%
Thin data	5 of 14 grade factors are computable; minimum is 7
Distress	CHS probability 1.766360%; universe top-decile threshold 1.068854%

What the price implies

at the 2026-10-05 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(30.6%)	8.0%	24
Distance from 52-week high	(88.8%)	(31.4%)	5

EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.77	0.28	79
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.58)	(0.14)	24

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$9.5M
Operating cash flow, four quarters	-\$9.0M
Months of runway	12.8
Days since last periodic filing	59 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	\$72,085

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$11.6M	2025-12-31	2026-03-27	10-K	0001567264-26-000024
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$9.2M	2025-12-31	2026-03-27	10-K	0001567264-26-000024
3	assets	us-gaap:Assets	\$14.1M	2025-12-31	2026-03-27	10-K	0001567264-26-000024
4	assets	us-gaap:Assets	\$4.8M	2024-12-31	2026-03-27	10-K	0001567264-26-000024
5	current assets	us-gaap:AssetsCurrent	\$12.7M	2025-12-31	2026-03-27	10-K	0001567264-26-000024
6	current liabilities	us-gaap:LiabilitiesCurrent	\$2.1M	2025-12-31	2026-03-27	10-K	0001567264-26-000024
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$78.4M	2025-12-31	2026-03-27	10-K	0001567264-26-000024
8	operating income	us-gaap:OperatingIncomeLoss	-\$12.0M	2025-12-31	2026-03-27	10-K	0001567264-26-000024
9	book equity	us-gaap:StockholdersEquity	\$11.9M	2025-12-31	2026-03-27	10-K	0001567264-26-000024
10	liabilities	us-gaap:Liabilities	\$2.2M	2025-12-31	2026-03-27	10-K	0001567264-26-000024
11	operating income	us-gaap:OperatingIncomeLoss	-\$8.3M	2023-12-31	2025-03-13	10-K	0001567264-25-000010
12	interest expense	us-gaap:InterestExpense	\$305,000	2023-12-31	2024-03-14	10-K	0001628280-24-011207
13	assets	us-gaap:Assets	\$17.3M	2023-12-31	2025-03-13	10-K	0001567264-25-000010
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,540,518	2026-03-26	2026-03-27	10-K	0001567264-26-000024
15	shares outstanding	dei:EntityCommonStockSharesOutstanding	15,180,945	2025-03-12	2025-03-13	10-K	0001567264-25-000010